Savara Inc (NASDAQ:SVRA) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Savara Inc (NASDAQ:SVRA) have received a consensus rating of “Moderate Buy” from the seven analysts that are covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $9.86.

A number of equities research analysts recently issued reports on SVRA shares. Evercore ISI reaffirmed an “in-line” rating and issued a $5.00 target price (down previously from $7.00) on shares of Savara in a research note on Wednesday, November 13th. Wells Fargo & Company started coverage on Savara in a research report on Friday, December 20th. They issued an “overweight” rating and a $8.00 price objective on the stock. HC Wainwright dropped their price objective on Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. Finally, JMP Securities restated a “market outperform” rating and issued a $9.00 target price on shares of Savara in a report on Thursday, December 19th.

Savara Trading Down 3.6 %

NASDAQ:SVRA opened at $2.70 on Friday. Savara has a 52-week low of $2.59 and a 52-week high of $5.70. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13. The stock has a fifty day simple moving average of $3.13 and a 200-day simple moving average of $3.72. The company has a market capitalization of $463.37 million, a PE ratio of -6.28 and a beta of 0.68.

Savara (NASDAQ:SVRA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.11). On average, equities research analysts expect that Savara will post -0.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Joseph S. Mccracken purchased 20,000 shares of the firm’s stock in a transaction on Tuesday, November 19th. The shares were bought at an average price of $2.95 per share, for a total transaction of $59,000.00. Following the acquisition, the director now directly owns 210,837 shares in the company, valued at $621,969.15. This trade represents a 10.48 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, CEO Matthew Pauls sold 54,702 shares of the business’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $3.31, for a total transaction of $181,063.62. Following the sale, the chief executive officer now directly owns 1,536,379 shares of the company’s stock, valued at $5,085,414.49. This represents a 3.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.13% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Savara

A number of large investors have recently modified their holdings of SVRA. Vestal Point Capital LP increased its position in Savara by 24.7% during the 3rd quarter. Vestal Point Capital LP now owns 8,090,000 shares of the company’s stock worth $34,302,000 after purchasing an additional 1,600,000 shares in the last quarter. Frazier Life Sciences Management L.P. grew its stake in Savara by 103.9% during the second quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock worth $32,874,000 after buying an additional 4,157,385 shares during the period. Geode Capital Management LLC increased its position in shares of Savara by 10.8% in the third quarter. Geode Capital Management LLC now owns 2,726,850 shares of the company’s stock worth $11,564,000 after acquiring an additional 264,825 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Savara by 238.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 911,617 shares of the company’s stock valued at $3,865,000 after acquiring an additional 642,259 shares during the period. Finally, Nantahala Capital Management LLC lifted its holdings in shares of Savara by 198.2% during the 2nd quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock valued at $20,879,000 after acquiring an additional 3,443,541 shares in the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.